Literature DB >> 28490218

Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients.

Youhei Fujiki1, Takuya Kotani1, Kentaro Isoda2, Takaaki Ishida1, Takeshi Shoda2, Shuzo Yoshida1, Tohru Takeuchi1, Shigeki Makino1.   

Abstract

OBJECTIVES: We retrospectively investigated clinical prognostic factors for interstitial pneumonia (IP) in anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive dermatomyositis (DM) patients.
METHODS: Subjects comprised 18 patients with anti-MDA5 Ab-positive DM-IP (9 survivors; 9 deaths).
RESULTS: Initial serum albumin levels, ferritin levels, and ground-glass opacity (GGO) scores in the right middle lobes were significantly higher in the death group than in the survivor group (p = .033, .013, and .005, respectively). Initial alveolar-arterial oxygen gradient (P[A-a]O2) was also higher in the death group than in the survivor group (p = .064). Initial serum ferritin, P[A-a]O2, and right middle lobe GGO score were found to significantly relate to death. Survival rates after 24 weeks were significantly lower among patients with an initial ferritin level of ≥450 ng/mL (25%), P[A-a]O2 of ≥30 mmHg (31%), and a right middle lobe GGO score of ≥2 (11%) than each of the others (p = .006, .020, and .002, respectively).
CONCLUSIONS: An initial serum ferritin level of ≥450 ng/mL, P[A-a]O2 of ≥30 mmHg, and right middle lobe GGO score of ≥2 (GGO ≥5% of the lobe) were identified as poor prognostic factors for anti-MDA5 Ab-positive DM-IP patients.

Entities:  

Keywords:  Dermatomyositis; interstitial pneumonia; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28490218     DOI: 10.1080/14397595.2017.1318468

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  17 in total

1.  Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.

Authors:  Lili Jiang; Youlian Wang; Qinglin Peng; Xiaoming Shu; Guochun Wang; Xiaomu Wu
Journal:  Clin Rheumatol       Date:  2019-02-09       Impact factor: 2.980

Review 2.  Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.

Authors:  Wanlong Wu; Li Guo; Yakai Fu; Kaiwen Wang; Danting Zhang; Wenwen Xu; Zhiwei Chen; Shuang Ye
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-06       Impact factor: 8.667

3.  A New Predictive Model for the Prognosis of MDA5+ DM-ILD.

Authors:  Qian Niu; Li-Qin Zhao; Wan-Li Ma; Liang Xiong; Xiao-Rong Wang; Xin-Liang He; Fan Yu
Journal:  Front Med (Lausanne)       Date:  2022-06-15

4.  Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome.

Authors:  Yinli Zhang; Yongpeng Ge; Hanbo Yang; He Chen; Xiaolan Tian; Zhenguo Huang; Shengyun Liu; Xin Lu; Guochun Wang
Journal:  Clin Rheumatol       Date:  2020-03-06       Impact factor: 2.980

5.  Interstitial lung disease with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis in elderly patients.

Authors:  Koichi Yamaguchi; Aya Yamaguchi; Miki Itai; Yuji Onuki; Yuki Shin; Shogo Uno; Chiharu Hanazato; Kohei Taguchi; Kazue Umetsu; Masaki Aikawa; Shunichi Kouno; Masao Takemura; Kenichiro Hara; Shinsuke Motegi; Mayuko Tsukida; Fumie Ota; Yoshito Tsukada; Mitsuru Motegi; Masao Nakasatomi; Toru Sakairi; Hidekazu Ikeuchi; Yoriaki Kaneko; Keiju Hiromura; Toshitaka Maeno
Journal:  Rheumatol Int       Date:  2021-05-30       Impact factor: 2.631

6.  The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease.

Authors:  Yumiko Sugiyama; Ryusuke Yoshimi; Maasa Tamura; Mitsuhiro Takeno; Yosuke Kunishita; Daiga Kishimoto; Yuji Yoshioka; Kouji Kobayashi; Kaoru Takase-Minegishi; Toshiyuki Watanabe; Naoki Hamada; Hideto Nagai; Naomi Tsuchida; Yutaro Soejima; Hiroto Nakano; Reikou Kamiyama; Takeaki Uehara; Yohei Kirino; Akiko Sekiguchi; Atsushi Ihata; Shigeru Ohno; Shouhei Nagaoka; Hideaki Nakajima
Journal:  Arthritis Res Ther       Date:  2018-01-11       Impact factor: 5.156

7.  Correlation of increased serum leucine-rich α2-glycoprotein levels with disease prognosis, progression, and activity of interstitial pneumonia in patients with dermatomyositis: A retrospective study.

Authors:  Takaaki Ishida; Takuya Kotani; Satoshi Serada; Minoru Fujimoto; Tohru Takeuchi; Shigeki Makino; Tetsuji Naka
Journal:  PLoS One       Date:  2020-06-01       Impact factor: 3.240

8.  Successful Treatment of Rapidly Progressive Unclassifiable Idiopathic Interstitial Pneumonia with Anti-melanoma Differentiation-associated Gene-5 Antibody by Intensive Immunosuppressive Therapy.

Authors:  Takuma Koga; Shinjiro Kaieda; Masaki Okamoto; Ken Masuda; Kyoko Fujimoto; Satoshi Sakamoto; Masayuki Nakamura; Masaki Tominaga; Tomotaka Kawayama; Kiminori Fujimoto; Tomoaki Hoshino; Hiroaki Ida
Journal:  Intern Med       Date:  2017-12-21       Impact factor: 1.271

Review 9.  Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.

Authors:  Juan González-Moreno; Manuel Raya-Cruz; Ines Losada-Lopez; Ana Paula Cacheda; Cristina Oliver; Bartomeu Colom
Journal:  Rheumatol Int       Date:  2018-02-07       Impact factor: 2.631

10.  The comparison of nailfold videocapillaroscopy findings between anti-melanoma differentiation-associated gene 5 antibody and anti-aminoacyl tRNA synthetase antibody in patients with dermatomyositis complicated by interstitial lung disease.

Authors:  Reiko Wakura; Shogo Matsuda; Takuya Kotani; Takeshi Shoda; Tohru Takeuchi
Journal:  Sci Rep       Date:  2020-09-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.